Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
Latest action · Feb 13, 2019 Read twice and referred to the Committee on Finance.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedFeb 13, 2019
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019
This bill requires manufacturers of drugs with specified percentage increases in their wholesale costs to submit to the Centers for Medicare & Medicaid Services (CMS) written justification for certain increases in drug prices. The CMS shall publish each submission, together with an easily understandable summary, on its website. Certain proprietary information may be excluded from publication, as specified by the bill.
A manufacturer that does not comply with the bill's requirements shall be subject to civil monetary penalties.
Cosponsors 12
Members who signed on, in the order they did. Signatures ran from Feb 13, 2019 to Sep 25, 2019; 8 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-MN | Amy Klobuchar | Original | Feb 13, 2019 |
| D-MD | Benjamin L. Cardin | Original | Feb 13, 2019 |
| D-DE | Christopher A. Coons | Original | Feb 13, 2019 |
| D-MI | Debbie Stabenow | Original | Feb 13, 2019 |
| D-MT | Jon Tester | Original | Feb 13, 2019 |
| D-NJ | Robert Menendez | Original | Feb 13, 2019 |
| D-IL | Tammy Duckworth | Original | Feb 13, 2019 |
| D-DE | Thomas R. Carper | Original | Feb 13, 2019 |
| D-NY | Kirsten E. Gillibrand | Mar 28, 2019 | |
| D-NV | Catherine Cortez Masto | Apr 30, 2019 | |
| D-MN | Tina Smith | Jul 10, 2019 | |
| D-MI | Gary C. Peters | Sep 25, 2019 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Finance Committee | Referred Feb 13, 2019 |
Actions 2
Everything that happened, newest first.
- Feb 13, 2019Introduced in Senate
- Feb 13, 2019Read twice and referred to the Committee on Finance.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| S. Hrg. 116-39 | DRUG PRICING IN AMERICA: A PRESCRIPTION FOR CHANGE, PART II1,108 pages | Finance Committee | Feb 26, 2019 |
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1348 | Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2017 | Reintroduction of | Jun 13, 2017 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to amend title XI of the Social Security Act to require drug manufacturers to publicly justify unnecessary price increases.
- Short Title(s) as Introduced
- Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Feb 13, 2019Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
